Introduction
The C-nucleosidesr epresent ag roup of nucleoside analogues in which the sugar moiety is linked to the nucleobase by ac arbon-carbon bond. [1] Several C-nucleosidesa re naturally occurring compounds. Among them, pseudouridinew as the first to be isolated from yeast tRNA in 1957. [2] Subsequently, other C-nucleosides,i ncludingo xazinomycin, [3] pyrazomycin, [3] showdomycin, [4] and formycin A, [5] were isolated from culture filtrates of different bacterial strains.T hese compounds are antibioticsa nd exhibit anti-cancer and/or antiviral activity.T heir advantageous properties arise from the presence of aC ÀCg lycosidic bond, which gives ag reater resistance than N-nucleosides towards chemical hydrolysis and enzymatic hydrolysis by phosphorylase andd eaminasee nzymes. On the basis of these interesting chemical and biological properties, aw ide variety of synthetic analogues have been prepared thanks to the large array of novel synthetic methodologies developed in the last two decades. Several of these compounds have found numerous applications in medicinal chemistry and chemical biology. [1] Amongt hem, pseudoisocytidine (PIC, 1), an ucleoside isostere of cytidinew as developed as ac andidate fora nti-leukaemic therapy [6] ( Figure 1 ). PIC was shown to be incorporated into both RNA and DNA and this incorporation was considered to be responsible for its therapeutic activity,w hich hasb een observed against several mousel eukaemias in vitro and in vivo. [7, 8] In addition, PIC was found to disruptD NA methylation by inhibition of the enzymeD NA methyltransferase, most probablydue to the presence of anitrogen atom in the 5-position of the base. [9] However,t he development of PIC was halted due to hepatotoxicity observed during phase Ic linical evaluation. [10] The efficiency with which PIC is incorporated into RNA, andt he rapid RNA turnover,a ssociated with protein synthesis in the liver,w ere considered the main causes of its hepatotoxicity.T hisf inding prompted the investigation of 2'-deoxypseudoisocytidine (2'd-PIC, 2), [11] which, in preliminary tissue culture experiments,w as found to exhibit inhibitory activity against P815 cell lines. [11a] PIC, 2'd-PIC andtheir analogues were also used as novel base-pairinga gents in oligonucleotides to investigate DNA and RNA structures andf unctions. [12] Althoughs everal C-nucleoside analogues have been described as anti-cancer and/or antiviral agents, none have ever been developed as anti-cancer or antiviral drugs.T he recent advent of two novel C-nucleosides, BCX4430 (3) [13] and GS-6620 (4), [14] as potentialt herapeutic agentsf or the treatment of the Ebola virus and hepatitis Cv irus (HCV) infections, respectively,h as stimulated renewed interest in this class of compounds ( Figure 1 ).
As part of our currentr esearch we wereinterested to further investigate the potential utility of 2'd-PIC (2)a sa na nti-leukaemic agent by preparing as eries of phosphoramidate prodrugs for biological evaluation as anti-cancera gents. "ProTides" in As yntheticp rocedure for the preparation of phosphoramidate prodrugs of C-nucleosidesi sr eported.D ifferent phosphorochloridates were reactedw ith 3'-O-protected N-acetyl-2'-deoxypseudoisocytidine or 3'-O-protected 2'-deoxypseudoisocytidine, followed by acidic hydrolysis of the protecting group. In the presenceo fthe N-acetyl moiety,t he enolisable keto group of the nucleobase was ablet or eact (like the 5'-OH) with the phosphorochloridates to give bisphosphorylated derivatives. Epimerisation (b to a)o ccurred if the amino group of the nucleobasew as unprotected. These side reactions demonstrate the peculiar behaviour of C-nucleosidesc ompared to their nucleoside analogues.I tw as demonstrated that the first enzymatic activation step for this new class of prodrugs can be mediated by carboxypeptidase andt hat it follows the same pathway and rate reportedf or ProTides of more conventional nucleoside analogues. These new phosphoramidate derivatives deservef urtheri nvestigation for their therapeutic potential as anti-cancer agents.
the clinic have consistently showed greater efficacy and more favourable safety profiles relative to the corresponding standard-of-care nucleoside analogues.S everal pharmaceutical companies have already validated the phosphoramidate approach for antiviral applications. In 2014, Gilead launched on the market itsanti-HCV ProTide, sofosbuvir (5) [15] and in the following year tenofovir alafenamide( TAF, 6), [16] an anti-HIV ProTide ( Figure 1 ). NuCana introduced the ProTide technology to clinicalo ncology with NUC-1031 (7), [17] aP roTide of gemcitabine, and NUC-3373( 8), [18] aP roTide of 2'-deoxy-5-fluorouridine, currently in phase III and phaseI clinical studies, respectively,f or patients with advanced solid tumours( Figure 1 ).
Results and Discussion

Synthesis of 2'-Deoxypseudoisocytidine (2)
Several approaches have been developed for the preparation of C-glycosides [19] and C-nucleosides. [20] Amongt hem, for the synthesis of 2'd-PIC( 2), we selected the methodology developed by Daves et al.,w hich utilisesaPd-catalysed Heck-type couplingo fa ryl halides to cyclic enol ethers, either pyranoid or furanoid glycals.
[21] As outlined in Scheme 1, the protected furanoid glycal 12 and the halogenated N-acetyl pseudoisocytosine 11,s erved as startingm aterials for the Heck reaction. 2-NAcetyl-5-iodoisocytosine (11)w as synthesised in good yield in two steps from commercially availablei socytosine (9) , which was first iodinated with N-iodosuccinimide in acetic acid to afford the intermediate compound 10.S ubsequent acetylation of the exocyclic amino function of 10 using acetic anhydride yielded the desired nucleobase 11. [22] Compound 12 was prepared from 3',5'-bis-O-(tert-butyldimethylsilyl)thymidine [23] by using typical silylation conditions first reported by Pedersen et al. [24] and then appliedb yH ammer et al. [25] for the preparation of furanose glycals with aw ide range of O-silyl protections.
The coupling reaction of 5-iodo base 11 with the protected ribofuranosyl glycal 12 using Pd(OAc) 2 as ac atalyst, AsPh 3 as as oft ligand and N,N-diisopropylethylamine as ab ase, formed selectively the b-C-nucleoside 13.A fter removal of the silyl groups with fluoride ions, the resulting2 '-deoxy-3'-keto C-nucleoside 14 was treated with sodium triacetoxyborohydride to reduce diastereoselectively the 3'-keto group from the b-face of the furanosyl ring, forming N-acetyl-2'-deoxypseudoisocytidine 15.
[22] The cleavage of the acetyl group to afford nucleoside 2 was then accomplishedb yb asic hydrolysisu sing NH 3 in MeOH.T he assignment of the configuration at the 1'-position of 2 was based on the comparison of its 1 HNMR spectrum with that reported in the literature. [22] 2.2. Synthesis of N-Acetyl-2'-deoxypseudoisocytidine Phosphoramidates
The two synthetic strategies commonly used for the preparation of phosphoramidate prodrugs (phosphorochloridate in the presence of either tert-butylmagnesiumc hloride or Nmethylimidazole as ab ase) [26] failed when appliedt o2,p robably due to the low solubility of the starting materiali nt he reaction medium, returning only unreacted startingm aterials. Attempts to improve the solubility of 2 using different solvents were unsuccessful.A pplication of the ProTide approacht op recursors 14 and 15 also failed, indicating that development of as uitable synthetic strategy to afford phosphoramidates of 2 was more challenging than originally expected. These results prompted us to use ad ifferent synthetic methodology with compound 17 as the key intermediate (Scheme 2).
We envisaged that introduction of a tert-butyldimethylsilyl ether at the 3'-OH group in 15 would help to improve its solubility and to achieve exclusive phosphorylation at the 5'-position.
In order to prepare compound 17,t he two hydroxy groups of deoxyribose present in N-acetyl-2'-deoxypseudoisocytidine (15)w ere first protected with a tert-butyldimethylsilyl group using tert-butyldimethylsilyl chloride in DMF for 24 ha tr oom temperature in the presence of 4-dimethylaminopyridine (DMAP)t op rovide, after flash chromatography,c ompound 16 in reasonabley ield. Then, selectives ilyl group deprotection was achievedw itha queous trifluoroacetic acid to give, after isolation by silica gel chromatography, 17 with af ree primary hydroxy group in moderate yield. Next, phosphorochloridates 18 a-f,p repared as am ixture of R P and S P diastereoisomers accordingt oaliterature procedure, [26] were reactedw ith 17 in the presence of tert-butylmagnesium chloride (1.0 m in THF), yielding3 '-O-tert-butyldimethylsilyl phosphoramidates 20 a-f (Scheme2)asdiastereoisomeric mixtures after column chromatography,e xcept for 20 d,w hich wasi solated after purification as as ingle diastereoisomer.D espite the almost complete consumption of the starting material, the desired products 20 a-f were recovered in low yields, which was ascribed in each case to the formation of ab isphosphorylated by-product, as exemplified in Figure 2 . The bisphosphorylated compound 19 f was isolateda nd its structure was characterisedb ym asss pectrometry and 31 Pa nd 1 HNMR analysis, [31] which clearly suggested that the phosphorylationinvolved the oxygen atom of the pyrimidine ring rather than either one of the nitrogen atoms. NAcetylisocytidine possesses an enolisablek eto group which, like the 5'-OH group, is able to react with ap hosphorochloridate to give an O-phosphorylated derivative. In support of this result,w ef ound in the literature that the reaction of 2-acetylamino-4-hydroxypyrimidines with phosphorochloridates gives O-phosphoryl rather than N-phosphoryl derivatives. [27] The substantials teric requirement of the phosphoryl chloride and the steric hindrance exerted to some extent by the acetylg roup were considered to be the key features for preventing phosphorylation at either one of the ring nitrogen atoms. [27] Acidic deprotection of 20 a-f afforded after preparative HPLC purification compounds 21 a-f in moderate yields (Scheme2and Table 1 ). Attempts to removet he acetyl protection from 21 a with Schwartz's reagent as described by Ferrari et al., [28] failed due to the ring openingo ft he base. The difficultiese ncountered in removing the N-acetyl group from 21 af using mild conditions, and the fact that the labile PÀOb ond of the ProTide would not tolerate other harsh de-acetylating agentss uch as methanolic ammonia,p romptedu st oa bandon our attempts toward modification of 21 a-f.W et herefore continued our effort to conceiveamore efficient route that would allow the preparation of the N-deacetylated analogues.
Synthesis of 2'-Deoxypseudoisocytidine Phosphoramidates
As shown in Scheme3,c ompound 22,o btained by treatment of 16 with methanolic ammonia, underwent selective5 '-desilylation using aqueous trifluoroacetic acid in THF to afford the monosilyl compound 23 in excellent yield. Next, phosphorochloridates 18 a and 18 g were reactedw ith 23 in the presence of tert-butylmagnesium chloride (1.0 m in THF) to yield, after columnc hromatography,t he 3'-O-tert-butyldimethylsilyl-protected phosphoramidates 24 a and 24 g in moderate yield as diastereoisomeric mixtures (Table 2) . No traces of bisphosphorylated products either due to O-o rN-phosphorylation were observed.
Acidic deprotectiono ft he tert-butyldimethylsilylm oieties in 24 a and 24 g with trifluoroacetic acid in dichloromethane (1:2 v/v;r oom temperature, overnight), afforded the final compounds 25 a and 25 g as mixtures of a and b isomersi na3:1 ratio after columnc hromatography.T he b-isomers of 25 a and 25 g were isolated in low yield after preparative HPLC purification (25 a as as ingle diastereoisomer and 25 g as am ixture; Scheme 3a nd Table 2 ). Most probably, the presence of ad issociable proton on N-1 facilitates the a,b-epimerisation in acidic conditions through aring opening-closure of the carbohydrate ring (Scheme 4) as previously reported for other C--nucleosides.
[11b, c, 29] If am ild procedure for the cleavageo ftert-butyldimethylsilyl ethers to alcohols (based on an exchange reactionw ith trimethylsilyl triflate at À78 8C) [30] was used, no epimerisation was observed.
Enzymatic Studieso nt he Activation of C-Nucleoside ProTides
To exert their biological activity,P roTides must be metabolised in vivo into the monophosphate form,w hich in turn generates the active triphosphate form by two consecutive phosphorylation reactions. [31] In the process of intracellular activation of ProTides, the first step is catalysed by ac arboxyesterase-type enzyme,s uch as cathepsin A, which was shown to be responsible for the cleavage of the amino acid ester moiety. [32] In order to demonstrate that the ProTides of C-nucleosidesa re activated in as imilar manner,t he interaction of compound 21 e with ac arboxyesterase-typee nzyme was investigated. Carboxypeptidase Yw as used as as urrogate of cathepsin Ab ecause it belongs to the same family of C-type carboxypeptidases and it was reported to share similarities in the active site. [33] Compound 21 e in [D 6 ]acetonew as therefore incubated in an NMR tube with carboxypeptidase Yi nT rizma buffer (pH 7.6), and the progress of the reactionw as monitored by 31 PNMR analysiso ver1 4h.T he stacked spectra ( Figure 3) show the formation of an ew peak after 10 min of incubation, which corresponds to intermediate I (d P = 5.06 ppm, t = 10 min). Complete conversion of the ProTide 21 e (which in [D 6 ]acetonea ppears as as ingle peak at d P = 4.26 ppm) into the correspondinga minoacyl phosphoramidate ester (II: d P = 7.19 ppm) was observed in 40 min. In vivo, the aminoacyl phosphoramidate ester metabolite is then believed to undergo PÀNb ond cleavage, mediated by ap hosphoramidase-type enzymet oe ventually release the parent drug in its monophosphate form.
Conclusions
An alternative route to C-nucleoside ProTides has been developed and used to preparep hosphoramidate derivatives of 2'd-PIC (2)a nd N-acetyl 2'd-PIC (15) . Unexpecteds ide reactions such as phosphorylationo ft he enolisable keto group of the nucleobase and epimerisation throughr ing openingh ighlighted the differentr eactivity of C-nucleosides compared to nucleoside analogues.The first carboxypeptidase-mediated bioactivations tep for this new class of prodrugs followed the same pathway and rate as reportedf or ProTides of conventional nucleoside analogues. Biological evaluation of these novel nucleoside analogues shoulde nhanceo ur understanding of the potentialo fC-nucleosides as anti-tumour agents and in particular of 2'd-PIC as an anti-leukaemic drug.T ogether with derivatives 25 a and 25 g,w ep lan to evaluate the N-acetylated derivatives 21 a-f for their anti-tumour activity.W ec onsidered that the acetyl moiety would further enhance the lipophilicity of these compounds and remove the potentialf or their protonation in vitro, whereas in vivo the acetyl moietyw ould most probably be able to undergo cleavage (thus acting as ad ual prodrug). The results of these investigationsw ill be disclosed in due course.
Experimental Section Chemistry
All anhydrous solvents were purchased from Sigma-Aldrich and amino acid esters from Novabiochem. All commercially available reagents were used without further purification. 
Low-resolution mass spectrometry was performed on aB ruker Daltonics micrOTOF-LC system.
For practical purposes, in some cases standard procedures are given. Procedures that differ from the standard are fully described.
N-(6-Oxo-1,6-dihydropyrimidin-2-yl)acetamide (10) N-Iodosuccinimide (22.0 g, 98 mmol) was added to as olution of 2-aminopyrimidin-4(3H)-one (9,1 0.0 g, 90 mmol) in acetic acid (170 mL) at 70 8C. The resulting suspension was heated at 100 8C and stirred for 1h.T he reaction mixture was cooled to room temperature and H 2 O( 500 mL) was added. The solid was filtered, washed with H 2 Oa nd dried with ah eat gun at 50 8Cf or 12 ht o afford compound 10 as al ight pink solid (12.8 g, 60 %y ield). N-(5-Iodo-6-oxo-1,6-dihydropyrimidin-2-yl)acetamide (11)
As uspension of 10 (11.8 g, 49.8 mmol) and acetic anhydride (11.8 mL, 124.5 mmol) in DMF (200 mL) was heated to 100 8C. After 1.5 ht he clear solution was evaporated to dryness under high vacuum and the residue was suspended in EtOH. The solid was filtered off and washed with Et 2 Ot oafford 11 as aw hite solid (9.2 g, 66 %y ield). (13) N,O-Bis(trimethylsilyl)-acetamide (9 mL, 7.5 g, 37 mmol) was added dropwise to as uspension of 11 (8.0 g, 29 mmol) in DMF (50 mL) under an argon atmosphere. After stirring for 1h the reaction become ac lear solution. Then N,N-diisopropylethylamine (6.3 mL, 4.67 g, 36 mmol) and 1,4-anhydro-3,5-O-bis(tert-butyldimethylsilyl)-2-deoxy-d-erythro-pent-1-enitol (12,4 .0 g, 11.6 mmol) were added. In as eparate flask, Pd(OAc) 2 (0.5 g, 2.2 mmol) was added to as olution of triphenylarsine (1.3 g, 4.2 mmol) in stirring DMF (100 mL). After 30 min, this solution was added slowly to the first flask and the mixture was stirred for 24 ha t8 0 8C. The reaction was quenched with the addition of H 2 O( 30 mL) and the solvent was evaporated under reduced pressure. The residue was redissolved in EtOAc (500 mL), and washed with H 2 O( 2 200 mL) and brine (200 mL). The organic layer was dried over MgSO 4 ,filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (EtOAc/hexane 7:3) to give 13 as al ight yellow solid (2.8 g, 52 %y ield). 70 %H F-pyridine (2.9 mL) was added dropwise to as olution of 13 (3.0 g, 6.0 mmol) in THF (100 mL). The reaction was stirred at room temperature for 12 hu nder an argon atmosphere. The suspension was diluted with acetic acid (30 mL) and the volatiles removed under reduced pressure to obtain crude compound 14,w hich was used in the next step without further purification. The residue was dissolved in am ixture of acetic acid/CH 3 CN (1:1 v/v,2 00 mL) and the mixture was cooled to À15 8C, followed by the portionwise addition of NaBH(OAc) 3 (3.0 g, 14.1 mmol). After 2h,t he mixture was evaporated to dryness under reduced pressure and the residue was purified by flash column chromatography (CH 2 Cl 2 /CH 3 OH 8:2) to give 15 as aw hite solid (1.3 g, 80 %y ield). (16) Imidazole (0.4 g, 5.8 mmol), tert-butyldimethylsilyl chloride (0.44 g, 2.9 mmol) and DMAP (0.04 g, 0.33 mmol) were added to as olution of 15 (0.34 g, 1.26 mmol) in DMF (2.5 mL) at room temperature under an argon atmosphere and the reaction was stirred at room temperature for 24 h. The reaction mixture was then quenched with CH 3 OH (1 mL) and the solvent was removed under reduced pressure. The residue was diluted with CH 2 Cl 2 (5 mL) and washed with H 2 O( 2mL), NaHCO 3 (2 mL) and brine (2 mL). The organic layer was dried over MgSO 4 ,f iltered and concentrated under reduced pressure. The crude product was purified by flash column chromatography (EtOAc/hexane 7:3) to give 16 as aw hite solid (0.410 g, 65 %y ield). 
N-(5-{(2'R,4'S,5'R)-4'-[(tert-Butyldimethylsilyl)oxy]-5'-(hydroxymethyl)tetrahydrofuran-2'-yl}-6-oxo-1,6-dihydropyrimidin-2-yl)acetamide (17)
Am ixture of TFAa nd H 2 O( 1:1v /v,2 .4 mL) was added dropwise to as olution of 16 (0.3 g, 0.6 mmol) in THF (4.8 mL) at 0 8C. The reaction mixture was stirred at room temperature for 2h under an argon atmosphere, then quenched with aqueous NaHCO 3 ;C H 2 Cl 2 was added and the aqueous phase was extracted twice with CH 2 Cl 2 .T he combined organic layers were dried over MgSO 4 ,f iltered and concentrated under vacuum to yield 17 as ag lassy solid (0.172 g, 75 %), which was used in the next step without further purification. 
Standard Procedure 1: Synthesis of Phosphorochloridates 18 a-g
Anhydrous triethylamine (2.0 mol equiv.) was added dropwise at À78 8Ct oas tirred solution of the appropriate amino ester hydrochloride/tosylate salt (1.0 mol equiv.) and the appropriate dichlorophosphate (1.0 mol equiv.) in anhydrous dichloromethane (61.6 mol) under an argon atmosphere. After 1hthe reaction mixture was allowed to warm to room temperature and was stirred for an additional 1-2 h. Formation of the desired phosphorochloridate was monitored by 31 PNMR spectroscopy.A fter the reaction was completed, the solvent was removed under reduced pressure and the resulting residue was re-dissolved in anhydrous diethyl ether and the triethylammonium salt was removed by filtration. The filtrate was evaporated to dryness and the crude material was purified by flash column chromatography with ethyl acetate/ hexane (1:1 v/v) as the eluent to give the desired phosphorochloridate as an oil.
Phenyl-(benzoxy-l-alaninyl)-phosphorochloridate (18 a)
Prepared according to standard procedure 1i n92 %y ield. 
Phenyl-(hexoxy-l-alaninyl)-phosphorochloridate (18 b)
Prepared according to standard procedure 1i n87 %y ield. 
Phenyl-(pentoxy-l-alaninyl)-phosphorochloridate (18 c)
Prepared according to standard procedure 1i n9 6% yield. 
1-Naphthyl-(benzoxy-l-alaninyl)-phosphorochloridate (18 f)
Prepared according to standard procedure 1i n78 %y ield. 
Phenyl-(isopropoxy-l-alaninyl)-phosphorochloridate (18 g)
Prepared according to standard procedure 1i n93 %y ield. Standard Procedure 2: Synthesis of 20 a-f, 24 aand 24 g
As olution of tBuMgCl in THF (1.0 m,1 .2 mol equiv.) was added at 0 8Ctoastirred solution of 17 or 23 (1 mol equiv.) in THF.The reaction mixture was allowed to warm to room temperature and the appropriate phosphorochloridate (2.0 mol equiv.) dissolved in anhydrous THF was added. The reaction mixture was stirred for 16-18 ha nd then evaporated under vacuum to give ac rude residue that was purified by column chromatography on silica gel, eluting with ag radient of CH 3 OH (0-5 %) in CH 2 Cl 2 to afford products 20 a-f, 24 a and 24 g as white solids.
Prepared according to standard procedure 2f rom nucleoside 17 (0.048 g, 0.137 mmol), 18 a (0.088 g, 0.27 mmol) in anhydrous THF (2.4 mL) and tBuMgCl in THF (1 m, 0.16 mL). After workup, the crude product was purified by column chromatography on silica gel using CH 2 Cl 2 /CH 3 OH (95:5) as eluent to provide 20 a as aw hite solid (22 mg, 25 %y ield). 
